First Time Loading...

Seagen Inc
NASDAQ:SGEN

Watchlist Manager
Seagen Inc Logo
Seagen Inc
NASDAQ:SGEN
Watchlist
Price: 228.74 USD -0.07% Market Closed
Updated: Jun 17, 2024
Have any thoughts about
Seagen Inc?
Write Note

Intrinsic Value

SGEN's intrinsic value estimate is unreliable because it is based only on its DCF value and doesn't use a relative valuation using multiples.

Seagen Inc. is a biotechnology company, which engages in the development and commercialization of antibody-based therapies for the treatment of cancer. [ Read More ]

The intrinsic value of one SGEN stock under the Base Case scenario is 35.41 USD. Compared to the current market price of 228.74 USD, Seagen Inc is Overvalued by 85%.

Key Points:
SGEN Intrinsic Value
Base Case
35.41 USD
Overvaluation 85%
Intrinsic Value
Price
Base Case Scenario

Valuation Backtest
Seagen Inc

Backtest Intrinsic Value
Dive into the past to invest in the future

Run backtest to discover the historical profit from buying and selling SGEN stocks based on their intrinsic value.

Analyze the historical link between intrinsic value and market price to make more informed investment decisions.

Run Backtest
Settings
Valuation Methods
Buy/Sell Thresholds
Buy When:
%
Sell When:
%
B
S
Run Backtest
How does it work?

Fundamental Analysis

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Seagen Inc

Current Assets 2.6B
Cash & Short-Term Investments 1.2B
Receivables 631.6m
Other Current Assets 683m
Non-Current Assets 1.1B
PP&E 487.7m
Intangibles 495m
Other Non-Current Assets 100m
Current Liabilities 954.7m
Accounts Payable 224.8m
Accrued Liabilities 729.9m
Non-Current Liabilities 129.1m
Other Non-Current Liabilities 129.1m
Efficiency

Earnings Waterfall
Seagen Inc

Revenue
2.3B USD
Cost of Revenue
-566.1m USD
Gross Profit
1.7B USD
Operating Expenses
-2.5B USD
Operating Income
-750.5m USD
Other Expenses
300k USD
Net Income
-750.2m USD

Free Cash Flow Analysis
Seagen Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
Fundamental Scores

SGEN Profitability Score
Profitability Due Diligence

Seagen Inc's profitability score is 27/100. The higher the profitability score, the more profitable the company is.

Positive Gross Profit
Exceptional Revenue Growth Forecast
Exceptional 1-Year Revenue Growth
Positive 3-Years Revenue Growth
27/100
Profitability
Score

Seagen Inc's profitability score is 27/100. The higher the profitability score, the more profitable the company is.

SGEN Solvency Score
Solvency Due Diligence

Seagen Inc's solvency score is 76/100. The higher the solvency score, the more solvent the company is.

High Altman Z-Score
Low D/E
Long-Term Solvency
Short-Term Solvency
76/100
Solvency
Score

Seagen Inc's solvency score is 76/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

SGEN Price Targets Summary
Seagen Inc

There are no price targets for SGEN.
Lowest
Price Target
Not Available
Average
Price Target
Not Available
Highest
Price Target
Not Available
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

Ownership

SGEN Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Shareholder Return

SGEN Price
Seagen Inc

1M 1M
-
6M 6M
-
1Y 1Y
+15%
3Y 3Y
+49%
5Y 5Y
+219%
10Y 10Y
+482%
Annual Price Range
228.74
52w Low
191.51
52w High
228.9
Price Metrics
Average Annual Return 33.51%
Standard Deviation of Annual Returns 34.65%
Max Drawdown -14%
Shares Statistics
Market Capitalization 43.1B USD
Shares Outstanding 188 663 008
Percentage of Shares Shorted 6.79%

SGEN Return Decomposition
Main factors of price return

What is price return decomposition?

SGEN News

Other Videos

Last Important Events
Seagen Inc

Significant happenings or occurrences that are of interest to investors. These could be company-specific developments or market-wide shifts.

All
Positive
Negative

Sentiment Analysis
Seagen Inc

Today
Last 7 Days 7D
Last 30 Days 30D
Last 90 Days 90D

Company Profile

Seagen Inc Logo
Seagen Inc

Country

United States of America

Industry

Biotechnology

Market Cap

43.1B USD

Dividend Yield

0%

Description

Seagen Inc. is a biotechnology company, which engages in the development and commercialization of antibody-based therapies for the treatment of cancer. The company is headquartered in Bothell, Washington and currently employs 2,675 full-time employees. The company went IPO on 2001-03-07. The firm is engaged in the development and sale of pharmaceutical products on its own, behalf or in collaboration with others. The firm is commercializing ADCETRIS, or brentuximab vedotin, for the treatment of certain CD30-expressing lymphomas; PADCEV or enfortumab vedotin-ejfv, for the treatment of certain metastatic urothelial cancers, and TUKYSA, or tucatinib, for treatment of certain metastatic HER2-positive breast cancers. The firm also develops a pipeline of therapies for solid tumors and blood-related cancers designed to address unmet medical needs. Its programs, including ADCETRIS and PADCEV, are based on its antibody-drug conjugate (ADC), technology that utilizes the targeting ability of monoclonal antibodies to deliver cell-killing agents directly to cancer cells. The firm's approved medicines include ADCETRIS, PADCEV and TUKYSA.

Contact

WASHINGTON
Bothell
21823 30Th Drive Se, Suite
+14255274000.0
https://www.seagen.com/

IPO

2001-03-07

Employees

2 675

Officers

Chief Financial Officer
Mr. Todd E. Simpson
Chief Legal Officer
Ms. Jean I. Liu J.D., M.S.
Exec. VP of Commercial U.S.
Mr. Charles R. Romp
Pres of R&D
Dr. Roger D. Dansey M.D.
CEO & Director
Mr. David R. Epstein B.Sc., M.B.A.
Chief Technical Officer
Dr. Vaughn B. Himes Ph.D.
Show More
Sr. VP of Investor Relations
Peggy Pinkston
VP of Corp. Communications
Mr. David Caouette
VP of Marketing
Mr. Matt Skelton
Exec. VP of HR
Mr. Christopher P. Pawlowicz
Show Less

See Also

Discover More
What is the Intrinsic Value of one SGEN stock?

The intrinsic value of one SGEN stock under the Base Case scenario is 35.41 USD.

Is SGEN stock undervalued or overvalued?

Compared to the current market price of 228.74 USD, Seagen Inc is Overvalued by 85%.